Last reviewed · How we verify
Befizal (BEZAFIBRATE)
At a glance
| Generic name | BEZAFIBRATE |
|---|---|
| Drug class | bezafibrate |
| Target | Fatty acid-binding protein, intestinal |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Hypercholesterolemia
- Hyperlipidemia
Common side effects
Key clinical trials
- CEDUR - German IBD Registry
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC (PHASE2)
- To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate (PHASE3)
- BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study (PHASE2)
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC (PHASE2)
- Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy (PHASE3)
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Befizal CI brief — competitive landscape report
- Befizal updates RSS · CI watch RSS